Kafrelsheikh University (Faculty of Physical Therapy)
Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt
Location status: Recruiting
NCT Number: NCT07351747
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.
Interested in participating?
Request Info20 year–35 year
Female
Interventional
Not applicable
Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt
Location status: Recruiting
Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus.
The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function.
Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive laser acupoints therapy addition to standard care.
Patients will receive placebo laser acupoints therapy in addition to standard care.
Time frame: 3 months post-treatment
Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.
Time frame: 3 months post-treatment
A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve.
Time frame: 3 months post-treatment
A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month.
Interested in participating?
Request InfoKafrelsheikh University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07653802
Crown Lengthening, Crown Lengthening Procedure With Ostectomy
Ajman, Ajman Emirate, United Arab Emirates
View Trial DetailsNCT07566507
Behavior, Exercise
Bari, Italy
View Trial DetailsNCT07467954
LASER, Skin Rejuvenation
Bandung, West Java, Indonesia
View Trial DetailsNCT07815132
Alzheimer Disease, Amyloid
Tanta, Egypt
View Trial Details